About N-Site – n-site.co.uk

N-Site is a free portal for Life Sciences companies where you can find a range of technical guidance notes on tax, legal and patent & trademark matters that impact the industry. Established by FTI Consulting in 2016 and developed in association with MedCity and the BioIndustry Association (BIA), the vision is that N-Site will become a primary resource for Expert Guidance for Life Sciences.

FTI Consulting

FTI Consulting’s European Tax Advisory practice comprises a wide range of leading industry specialisms one of which is a unique team supporting Life Sciences.

With a dedicated sector focus, FTI Consulting has been able to develop a number unique offerings for Life Sciences companies to support them in a range of tax matters including licensing, enhancing R&D tax reliefs, pharmaceutical transfer pricing and advanced tax modelling for financial forecasting.

For more details click here.

Taylor Wessing

Life Sciences is one of the most innovative and complex market sectors. It is currently undergoing a period of intense transformation, with companies facing an ever-increasing level of regulation as well as strict cost management in order to remain competitive and profitable.

Taylor Wessing’s Life Sciences team is widely regarded as one of the market leaders, providing a distinct legal service to pharmaceutical, biotech, medical device, diagnostics and research tool companies, as well as service providers in this sector.

The firm advises start-ups to major multinational organisations on every aspect of the product life cycle, from discovery and development through to end-of-life patent disputes.

It’s recognition is based on the extensive international expertise the group has in advising across the full range of areas that are central to the business of any life sciences company, including patent litigation, fund formation, venture capital, regulatory advice and licensing.

For more details click here.

Gill Jennings & Every

GJE is a leading intellectual property firm based in London and Munich. They provide the ideal combination of legal, technical and commercial expertise to help turn innovations, brands and designs into commercial success.

They understand the importance of intellectual property to Life Sciences businesses and by providing clear, creative and expert advice they can assist in protecting, exploiting and managing IP assets to maximise their value.

GJE offers unique consultancy services, known as ConsultIP™, that benefit Life Sciences businesses at every stage of their life cycle – from developing and implementing an IP strategy, to ensuring they are due diligence ready, either to attract investment or secure an exit.

GJE are consistently recognised by the leading UK legal directories – Chambers, Legal 500 and Managing Intellectual Property – as a ‘go-to’ firm, which is a testament to the quality of their advice and the valued role they play in supporting their clients.

For more details click here.

Gallagher

Gallagher’s UK Life Sciences Practice looks after around 400 life science clients and have been together for over 25 years, resulting in experience across a diverse range of innovative companies operating in the life sciences sector. This extensive experience and market power alongside their long-standing relationships with specialist life science insurers enables them to leverage the market and provide comprehensive, competitive and at time exclusive insurance packages for their clients.

For more details click here.

PharmaVentures

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, M&A deals and strategic alliances. For the past 28 years, PharmaVentures has acted as advisor on over 700 deal related projects covering licensing, mergers, acquisitions, divestments and joint venture activities for companies world-wide.

Their unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes them uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

Their services include:

M&A (divestments, mergers, acquisitions and strategic transactions)
Strategy (commercialisation, deal strategy, due diligence, market entry)
Valuation and Positioning (licensing, M&A, fund raising & expert testimonies)
Licensing (in and out licensing)
Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)
Fundraising

PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in N. America, Latin America, Asia-Pacific.

For more details click here.

Virdis Group

Virdis Group is a global Life Science executive search and organisational consultancy. Established in 2007, with offices in Oxford (UK), Lausanne (Switzerland, Biopôle) and Boston (MA, USA), we partner with clients throughout the world.

Our focus is to identify, engage and help hire top talent from Executive to Board levels, covering a broad range of roles, from R&D to Commercial. We challenge constructively. As a partner, we bring the best organisational solutions; sharing our experience and lateral thinking.

Our services are flexible and tailored to fit our clients’ needs, matching their values and high standards. To offer the best, we attend international conferences, lead business workshops and support scientific events. As such, we develop industry knowledge and a network of established relationships, which help create a safety net and mitigate the risk inherent to building teams and organisations.

Our vision is a world where Life Science businesses have trusting and meaningful relationships with the communities they serve.

Our mission is to create and build Life Science companies where the talent we hire thrive to develop medicines and technologies which protect the health of us all.

For more details click here.

MAP BioPharma

MAP BioPharma is a Market Access specialist. We accelerate patient access to medicines, devices and diagnostics.

Offering a unique integrated approach that blends online resources with supportive consultancy, MAP can support the journey throughout the product lifecycle. Our expert team helps you navigate the complexities of Market Access. Our services include:

MAP Online

The only validated Market Access resource that details all the processes, policies, and stakeholders you need to know to plan your Market Access journey. Updated daily, it provides extensive information, coupled with the MAP Online team who are on hand to answer any questions. This virtual expert helps you stay on top of an ever-changing Market Access environment

Market Access Consultancy

MAP BioPharma has a highly experienced team of Market Access consultants with over 200 years of collective experience managing a wide range of Market Access challenges across international markets. Our expertise includes: Market Access strategy & Pricing, HTA submissions, Health Economics & Outcomes Research, and Patient Engagement

Market Access Tools

A suite of best-in class templates, calculators and forecasting models saving you time and money.

For more details click here.

FTI Cybersecurity

FTI Consulting’s global cybersecurity practice is made up of recognised expertise from across industry, government and academia. We help clients solve cyber security challenges: we help secure new technologies and supply chains; we help defend against the attentions of increasing volumes and innovative threats; we help ensure compliance in the face of increasing regulatory security, and we focus on fit-for-purpose value from finite resources available.

The Life Sciences sector is targeted by some of the most sophisticated cyber adversaries. Working closely with our European FTI colleagues specialising in Life Sciences, we help clients respond to these threats, increase their security posture in a cost-effective manner and plan their investments in a secure, compliant and future-proof manner. Our offerings cover proactive, responsive and remediation activities, and include:

Responding to cyber breaches and incidents, and investigating underlying issues.
Understanding, prioritising and managing cyber risks proactively.
Hardening and improving security posture in a cost-effective manner.
Educating and protecting key decision makers and securing their digital footprints, as executives remain key targets for cyber attacks in Life Sciences.
Assessing and hardening supply chain security, mitigating third party risks.

For more details click here.

MedCity

MedCity is a collaboration between the Mayor of London and the capital’s three Academic Health Science Centres – Imperial College Academic Health Science Centre, King’s Health Partners, and UCL Partners. Launched in April 2014 to promote and grow the UK’s world-leading life sciences clusters, it is promoting life sciences investment, entrepreneurship and industry in the region by:

Providing a single front door and concierge service for industry and investors looking for partners, infrastructure and expertise
Facilitating and supporting collaboration across all parts of the sector to turn innovations into commercial products and services
Fostering an environment that supports and encourages entrepreneurialism
Raising awareness globally of the region’s rich life sciences ecosystem

It is supported by the Higher Education Funding Council for England and the Mayor of London and works with academics, research and NHS institutions, as well as local enterprise partnerships and the Mayor’s official promotional organisation London & Partners.

For more details click here.

BioIndustry Association (BIA)

The BIA is the trade association for innovative enterprises involved in UK bioscience. BIA’s goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives.

The BIA is at the forefront of UK bioscience, serving as its voice, connecting individuals and organisations, from SMEs, including innovative start-ups, to multi-national companies, helping to shape the future of the sector.

BIA’s members are responsible for over 90% of biotech medicines currently in clinical development in the UK. In the last year, BIA members have taken forward pioneering research such as the first stem cell therapy clinical trials for stroke and the first drug to delay bone metastases in cancer.

The BIA pushes for progress in UK bioscience on every front. Their goal is to deliver the best possible environment for growth and innovation.

For more details click here.